摘要
目的探讨异基因造血干细胞移植(allo-HSCT)治疗慢性淋巴细胞白血病(CLL)的安全性和有效性。方法总结分析3例行HLA全相合allo-HSCT治疗的年轻CLL患者的临床特征、实验室检查指标、移植经过及转归,并进行相关文献复习和讨论。结果 3例患者年龄均在50岁以下,Rai分期属于高危组,给予allo-HSCT治疗,白细胞植活中位时间为12(11～13)d,血小板植活中位时间为13(12～14)d。移植后出现慢性局限皮肤型移植物抗宿主病(GVHD)1例。随访至2012年4月,平均随访时间25(10～53)个月,3例均无病生存。结论 allo-HSCT是CLL唯一具有治愈可能的手段,有合适供者的年轻高危CLL患者可考虑行造血干细胞移植。
Objective To investigate the reliability and efficiency of allogeneic hematopoietic stem cell transplantation （Allo-HSCT） in the treatment of chronic lymphocytic leukemia （CLL） in young patients. Methods The clinical features, laboratory manifestations, transplantation options and prognosis of 3 young male patients （35 to 44 years old） who received HLA-matched allogeneic hematopoietic stem cell transplantation in our department during October 2010 to June 2011 were collected and analyzed. The related literature was also reviewed. Results The 3 patients were all younger than 50 years old, and belonged to high risk group in Rai stage. The mean time of leukocytes engraftment was 12 d （ranging from 11 to 13 d）, and the mean time of platelets engraftment was 13 d （ranging from 12 to 14 d）. Chronic localized graft-versus-host disease （cGVHD） of the skin was found in 1 patient. Three patients were followed up till April 2012 （mean 25 months）. All of three patients had a disease-free-survival. Conclusion Allo-HSCT is the only method having a possibility to cure CLL. We suggest that Allo-HSCT should be used for young high-risk CLL patients with suitable donors.
出处
《第三军医大学学报》
CAS
CSCD
北大核心
2012年第24期2446-2448,共3页
Journal of Third Military Medical University
关键词
造血干细胞移植
慢性淋巴细胞白血病
hematopoietic stem cell transplantation
chronic lymphocytic leukemia
